Carna Biosciences, Inc. (TYO:4572)
Japan flag Japan · Delayed Price · Currency is JPY
307.00
-10.00 (-3.15%)
Nov 18, 2026, 10:30 AM JST

Carna Biosciences Income Statement

Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
756.575796361,6251,3862,017
Revenue Growth
38.96%-8.96%-60.86%17.24%-31.28%78.02%
Cost of Revenue
221.26191171175171135
Gross Profit
535.313884651,4501,2151,882
Selling, General & Admin
740.46612655664603572
Research & Development
1,8511,8511,8861,9031,8821,841
Operating Expenses
2,5912,4632,5412,5672,4852,413
Operating Income
-2,056-2,075-2,076-1,117-1,270-531
Interest Expense
-74.2-52-3-4-6-4
Interest & Investment Income
2.48514---
Currency Exchange Gain (Loss)
-18.31-2326--14
Other Non Operating Income (Expenses)
-1.77-1-42-5-3-3
EBT Excluding Unusual Items
-2,148-2,146-2,081-1,126-1,279-524
Asset Writedown
-34.34-24-93-4-44-9
Other Unusual Items
-20-----
Pretax Income
-2,202-2,170-2,174-1,130-1,323-533
Income Tax Expense
1.711422261
Net Income
-2,204-2,171-2,178-1,152-1,349-534
Net Income to Common
-2,204-2,171-2,178-1,152-1,349-534
Net Income Growth
------
Shares Outstanding (Basic)
201918171413
Shares Outstanding (Diluted)
201918171413
Shares Change
4.09%6.71%6.61%23.37%7.26%3.22%
EPS (Basic)
-111.01-113.60-121.61-68.57-99.06-42.06
EPS (Diluted)
-111.01-113.60-121.61-68.57-99.06-42.06
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
--2,168-1,387-1,688-834-1,577
Free Cash Flow Per Share
--113.44-77.44-100.48-61.24-124.22
Gross Margin
70.75%67.01%73.11%89.23%87.66%93.31%
Operating Margin
-271.77%-358.38%-326.41%-68.74%-91.63%-26.33%
Profit Margin
-291.31%-374.96%-342.45%-70.89%-97.33%-26.47%
Free Cash Flow Margin
--374.44%-218.08%-103.88%-60.17%-78.19%
EBITDA
--2,044-2,045-1,082-1,237-512
EBITDA Margin
----66.59%-89.25%-25.38%
D&A For EBITDA
-3131353319
EBIT
-2,056-2,075-2,076-1,117-1,270-531
EBIT Margin
-271.77%---68.74%-91.63%-26.33%